Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations
Phase 4 Study of Nasea(R)/Ramosetron Inj.as Anti-emetics in the Patients Undergoing Facial Bone Fracture Operations
研究概览
详细说明
Participants
- 100 patients with undergoing facial bone surgery are going to be randomly allocated to one of the 3 groups
Randomization
- G1(n=33) - Ramosetron 0.3mg i.v. just before the beginning of the surgery
- G2(n=33) - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
- G3(n=33) - No medication but regular antiemetics i.v. if the patient wants
The primary endpoint
- the incidence of nausea and vomiting for 24 h after surgery at 0-6h, 6-12 h and 12-24 h
The secondary endpoints
- the severity of nausea, need for rescue medication
- patient satisfaction with efficacy
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、大韩民国、463-707
- Seoul National University Bundang Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patient who sign informed consent form for the study
- patient who are considered as surgical candidates with facial bones fracture
Exclusion Criteria:
- Patient who have had nausea/vomiting episodes
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:Preop. ramosetron 0.3mg i.v.
G1 - Ramosetron 0.3mg i.v.
just before the beginning of the surgery
|
G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room G3 - No medication but regular antiemetics injection if the patient want
其他名称:
|
有源比较器:Postop. ramosetron 0.3mg i.v.
G2 - Ramosetron 0.3mg i.v.
just after the end of the surgery and moving into the Recovery room
|
G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room G3 - No medication but regular antiemetics injection if the patient want
其他名称:
|
有源比较器:No Ramosetron
G3 - No medication but regular antiemetics injection if the patient wants
|
G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room G3 - No medication but regular antiemetics injection if the patient want
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
incidence and severity of nausea and vomiting
大体时间:for 24 h after surgery at 0-6h, 6-12 h and 12-24 h
|
for 24 h after surgery at 0-6h, 6-12 h and 12-24 h
|
次要结果测量
结果测量 |
大体时间 |
---|---|
patient satisfaction with the effect
大体时间:at 24 h after surgery
|
at 24 h after surgery
|
合作者和调查者
调查人员
- 首席研究员:Chanyeong Heo, Ph.D.、Seoul National University Bundang Hospital
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
面部骨折的临床试验
-
Bausch Health Americas, Inc.终止
-
Lisa M. Guay-WoodfordNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)招聘中肾炎 | 茹伯特综合症 | Bardet Biedl 综合症 | 常染色体隐性多囊肾病 | 先天性肝纤维化 | 肝/肾纤维囊性疾病 | 梅克尔-格鲁伯综合症 | 卡罗利综合症 | Oro-Facial-Digital 综合症 I 型 | 肾小球囊性肾病美国